<p>Cytomegalovirus (CMV), known for its high transcriptional activity in eukaryotic cells. The CMV promoter has been demonstrated to be highly efficacious in facilitating the expression of lengthy and complex genes within HEK-293T cells.[3]</p>
+
<p>To achieve the objective of driving the expression of the MT1 melatonin receptor, we strategically selected the CMV promoter, a robust promoter derived from the human Cytomegalovirus (CMV), known for its high transcriptional activity in eukaryotic cells. The CMV promoter has been demonstrated to be highly efficacious in facilitating the expression of lengthy and complex genes within HEK-293T cells.[3]</p>
<p>Utilizing the CMV promoter, we initiated the transcription of the MT1 gene within the construct of the gene expression vector, thereby enhancing the expression profile of the MT1 gene. This approach is anticipated to provide a foundation for the development of a cell-based screening platform for melatonin receptor agonists.</p>
<p>Utilizing the CMV promoter, we initiated the transcription of the MT1 gene within the construct of the gene expression vector, thereby enhancing the expression profile of the MT1 gene. This approach is anticipated to provide a foundation for the development of a cell-based screening platform for melatonin receptor agonists.</p>
Revision as of 05:22, 1 October 2024
P_CMV->MTNR1A->bGH_polyA
Expression of MT1 gene
Sequence and Features
Assembly Compatibility:
10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
INCOMPATIBLE WITH RFC[21]
Illegal BglII site found at 614 Illegal BamHI site found at 1255 Illegal BamHI site found at 1435
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]
Profile
Name: P_CMV->MTNR1A->bGH_polyA
Base Pairs: 1909bp
Origin: Homo sapiens
Properties: Expression of MT1 gene
Usage and Biology
The melatonin receptors (MTs), specifically MT1 (melatonin receptor type 1) and MT2 (melatonin receptor type 2), are classified under the G protein-coupled receptor (GPCR) family A, with melatonin acting as their endogenous agonist. These receptors are pivotal in the regulation of the circadian rhythm within the human body and are intricately linked to a spectrum of vital physiological processes, including reproductive function, neuronal modulation, and immune system regulation. Furthermore, MTs represent a significant therapeutic target for the amelioration of various pathologies, such as insomnia, affective disorders, and oncological conditions.[1].
Despite the high degree of homology between human MT1 and MT2 receptors, there are considerable differences in their tissue distribution, intracellular signaling mechanisms, and physiological roles. The current dearth of selectivity in melatonin-based pharmaceuticals for either MT1 or MT2 receptors impedes the precision therapy of related disorders. Consequently, the detailed structural elucidation of the MTs agonist binding site is of paramount importance for the development of targeted pharmacotherapeutics.[2]
In light of this, we have engineered a pathway that, upon promoter activation, initiates the synthesis of the MT1 melatonin receptor protein. This strategy is instrumental in the establishment of a cellular assay system designed for the screening of melatonin receptor agonists.(Figure 1)